Genentech: Jacqueline M McBride | Director and Principal Scientist, OMNI Biomarker Development

Scientists / Our Scientists

"Imagination is more important than knowledge"

Years at Genentech

Publications

Awards & Honors

I am native Scot and Basic Immunologist. I began my science career at the university of Glasgow in one of the first Immunology degree courses offered in the UK. I continued to grow my passion for science in Europe at the IMP Biocenter in Vienna looking to understand the mechanisms of dendritic cell tolerance. From here I sought to expand my knowledge in Clinical Immunology at Stanford School of medicine and then joined the postdoctoral program at Genentech in Immunology discovery. I soon realized my passion and curiosity was in biotechnology and translational science and joined the OMNI-Biomarker development group in Development Sciences as a Scientist. I currently work as a Scientist and a Biomarker Subteam leader and supporting the development of novel therapeutics such as Influenza A, Etrolizumab, and anti- PD-L1 combos.

Featured Publication

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.

Arthritis Rheum. 2012 Nov;64(11):3666-76.

McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, Maciuca R, Townsend M, Wallace DJ, Kennedy WP, Drappa J.

View Abstract

I am currently a Scientist and Biomarker subteam leader for both early and late stage development molecules. Internally I collaborate with many functions from research through development to drive the delivery of a safe and efficacious product. Externally I also engage with global thought leaders and investigators, which allows the generation of vital knowledge and technologies in specialized patient populations that inform the development of our clinical candidates. I am accountable for the delivery of both predictive and pharmacodynamics biomarker strategies, providing high quality assays and data. These goal of my work is to enable decision making including refining our knowledge of the MOA of a given molecule, inform dose selection, demonstrating proof of activity in pre-clinical and clinical studies, and mechanistic differentiation from competitor molecules. I am fortunate to have worked in many disease indications including Autoimmune diseases, infectious Diseases and Oncology.

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade

Journal for ImmunoTherapy of Cancer,

Romain Banchereau; Avantika S. Chitre; Alexis Scherl; Thomas Wu; Namrata S. Patil; Patricia De Almeida; Edward E. Kadel III; Shravan Madireddi; Amelia Au-Yeung; Chikara Takahashi; Jasmine Chen; Zora Modrusan; Jacqueline McBride; Rhea Nersesian; Ehab A. El-Gabry; Mark D. Robida; Jeffrey Hung; Marcin Kowanetz; Wei Zou; Mark McCleland; Patrick Caplazi; Shadi Toghi Eshgi; Hartmut Koeppen; Priti Hegde; Ira Mellman; Rod Mathews; Thomas Powles; Sanjeev Mariathasan; Jane Grogan; William E. O'Gorman

A phase 2 randomized, double-blind, placebo-controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir in patients hospitalized with severe influenza a virus infection

Antimicrobial Agents and Chemotherapy, ISSN: 10986596 00664804

Jeremy Lim; Anna C. Nilsson; Michael Silverman; Nimer Assy; Priya Kulkarni; Jacqueline McBride; Rong Deng; Chloe Li; Xiaoying Yang; Allen Nguyen; Priscilla Horn; Mauricio Maia; Aide Castro; Melicent Peck; Joshua Galanter; Tom Chu; Elizabeth Newton; Jorge Tavel

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Jacqueline M McBride

Director and Principal Scientist, OMNI Biomarker Development

Featured Publication

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.